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provide lower bounds of prevalence estimates. Schizophrenia is
most prevalent in the low income and uninsured populations
than in the privately insured or Medicare populations.
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OBJECTIVE: To determine the incremental cost-effectiveness for
treating schizophrenia patients with olanzapine versus risperi-
done, quetiapine, amisulpride, or oral typical antipsychotics.
METHODS: European SOHO is a 3-year, prospective, outpa-
tient, observational study associated with antipsychotic treat-
ment in 10 European countries. Health care resource use and
clinical effectiveness data were collected at baseline, 3, 6, and 12
months. Clinical effectiveness was assessed using the Clinical
Global Impression (CGI) scale. UK health care costs were applied
to resource use data for the 10 countries. Pair-wise incremental
costs and effectiveness were estimated between olanzapine-
treated patients and patients treated with each of the other oral
antipsychotics. Incremental cost-effectiveness ratios (ICERs)
were presented as the additional cost per CGI unit gained.
RESULTS: A total of 10,972 patients were enrolled at baseline,
80% were eligible for analyses at 12 months. Pair-wise cost-
effectiveness comparisons, over 12 months, showed treatment
with olanzapine is more effective and less costly than quetiapine
and amisulpride. Treatment with olanzapine is more effective
compared to treatment with risperidone and marginally more
costly: £226 per patient over 12 months. The incremental cost-
effectiveness ratio was £1299 per additional decrease in CGI unit
gained. Treatment with olanzapine is more effective than oral
typical antipsychotics and marginal more costly: £849 per
patient over 12 months. The incremental cost-effectiveness ratio
for olanzapine versus oral typical treatment was £3166 per addi-
tional decrease in CGI unit gained. Treatment maintenance was
77% at 12 months with olanzapine, which was greater than that
for the other treatments. CONCLUSIONS: Olanzapine was cost
saving and more effective than treatment with quetiapine and
amisulpride. The cost-effectiveness of olanzapine compared to
respirodone and typicals depends on the value assigned to the
decrease in GCI unit gained. This needs to be considered,
however, in the context of treatment maintenance, which
favoured olanzapine.
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OBJECTIVE: The aim of this study was to estimate the cost-
effectiveness of treatment with ziprasidone vs. no-treatment
(placebo) for schizophrenia relapse prevention, in Spain.
METHODS: Treatment of schizophrenia was modeled over one
year, by means of a retrospective deterministic model, from the
National Health System (NHS) perspective (year 2005). The
primary outcome was the probability of relapse occurring within
a 52 weeks period of treatment with ziprasidone daily doses of
40–160mg vs. placebo. Data was obtained from a randomized,
double-blind, placebo-controlled clinical trial (N = 218 patients).
Antipsychotic cost, concomitant drugs to treat adverse events
(extrapiramidal symptoms, etc.) and medical costs associated to
adverse events were derived from the clinical trial results and
from a Spanish Health Cost database. The average cost of a
patient with acute psychosis relapse admitted to hospital in Spain
(€3421) was obtained from a retrospective analysis of medical
records of 200 patients admitted for acute psychosis in eight
Spanish hospitals (The Psychosp Study), previously published.
RESULTS: The probability of psychosis relapse was 0.77 with
placebo, and 0.43, 0.35, 0.36 and 0.38 for ziprasidone daily dose
of 40, 80, 160mg or weighted doses, respectively (p < 0.01 vs.
placebo in all cases). The number needed to treat (NNT) to avoid
1 relapse was 1.3 (95% CI 1.2–1.4), 2.3 (2.0–2.8), 2.9 (2.4–3.7),
2.8 (2.2–3.3), and 2.6 (2.2–3.3), respectively. The yearly average
incremental cost per relapse avoided was €186 for the weighted
dose of ziprasidone, and ranged from savings of €557 
(80mg/day) to incremental of €1015 (160mg/day), lower in all
cases than the cost of a relapse (€3421). CONCLUSIONS:
According to this evaluation, and compared with no treatment,
the psychosis relapse prevention with ziprasidone is cost-
effective from the Spanish NHS perspective.
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OBJECTIVES: Schizophrenia is a chronic, disabling and costly
disease which affects 2.2 million in US. No study has looked at
the patterns of drug therapy and cost of the disease in a previ-
ously insured population and how closely treatment guide-
lines are followed. Problem: Using data from Blue Shield of 
California, we determine drug utilization patterns and costs and
the relationship between these patterns and the American Psy-
chiatric Association treatment guidelines and total costs of schiz-
ophrenia treatment. METHODS: We used claims data from Blue
Shield of California during 2001–2004 to select all patients with
ICD-9 diagnoses of schizophrenia. Data was available for uti-
lization and costs of health care use, including mental health
carve-out care. We used a 6 month run-in and ending period in
case of incomplete claims data. Drug categories were typical and
atypical antipsychotics and mood stabilizers. Drug patterns were
monotherapy, combination therapy with and without mood sta-
bilizers, and several switch patterns. We used chi-square tests and
linear regression analysis to detect associations between utiliza-
tion patterns and costs. RESULTS: The 799 schizophrenia
patients had a mean age of 42.6 years (20.4–86.2) and 46.3%
were males. Total annual direct costs of treatment were
$6301/patient, 46% acute care services, and 45% prescription
drugs. The combination treatment group (2 antipsychotics/mood
stabilizer) as well as a monotherapy group (one switch antipsy-
chotic therapy) had the highest utilization and costs. Our regres-
sion showed higher total costs correlated with males and patients
with an average of 1.8 therapy switches while on otherwise single
stable antipsychotic therapy. Older patients and those on a mood
stabilizer contributed the least to cost. CONCLUSION: The
total annual costs of these insured schizophrenic patients
($6301) were substantially lower than the $25,940 reported for
Medicaid patients. Health care utilization and costs increased as
